Stamford, CT -- (SBWIRE) -- 01/16/2014 -- Jet Life Penny Stocks is engaged in providing the most up to date and useful information on the Best Penny Stocks that are poised to breakout. Our penny stock newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. Here are some of the most awesome penny stocks we came up with that the ‘underground penny stock experts’ are always bragging about in their penny stock newsletters. Have a look on today’s market movers: Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP), Ibio Inc (NYSEMKT:IBIO), Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) opened the session at $26.27, trading in a range of $21.25 - $26.30. The stock showed a negative performance of -13.10% in the last trading session from its previous close of $26.41 and closed at $22.95. The stock traded on a volume of 1.32 million shares and the average volume of the stock remained 795,321 shares. Oramed Pharmaceuticals Inc. is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides.
Has ORMP Found The Bottom and Ready To Move Up? Find Out Here
Ibio Inc (NYSEMKT:IBIO) traded 1.75 million shares in the last business day while the average volume of the stock remained 290,284 shares. The stock showed a negative movement of -11.16% to end at $0.520. The 52 week range of the stock remained $0.28 - $0.93. iBio, Inc. (iBio) is a biotechnology company focused on commercializing its technologies, the iBioLaunch platform for vaccines and therapeutic proteins, as well as the iBioModulator platform for vaccine enhancement. Vaccine candidates on its platform are applicable to newly emerging strains of hemagglutinin type 1 and neuraminidase type 1 (H1N1), swine-like influenza, hemagglutinin type 5 and neuraminidase type 1 (H5N1) avian influenza, yellow fever, and anthrax.
Has IBIO Found The Bottom And Ready To Gain Momentum? Find Out Here
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) reported 34.28 million shares were exchanged during the last trade, while the average volume is about 8.71 million shares. The stock dropped -10.34% and finished the day at $1.04. The beta of the stock is recorded at 1.83. Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company’s pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates.
Why Should Investors Buy RNN After the Recent Fall? Just Go Here and Find Out
Idera Pharmaceuticals Inc (NASDAQ:IDRA) shares dropped, -8.90 percent from its previous close of $4.83 to close at $4.40. Traded with volume of 3.07 million shares in the prior session and the average volume of the stock remained 2.63 million shares. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs).
Will IDRA Get Buyers Even After The Recent Rally? Find Out Here
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Our Penny Stock Newsletter also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Read full disclaimer at: http://www.jetlifepennystocks.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)